vorsetuzumab

Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a monoclonal antibody that targets the CD70 antigen. It exhibits anticancer activity by enhancing macrophage-associated phagocytosis of kidney cancer cells and inhibiting Burkitt lymphoma.

Vorsetuzumab mafodotin (SGN‑75) is an auristatin-based, CD70-targeted antibody-drug conjugate (ADC), composed of the humanized monoclonal antibody Vorsetuzumab and the ADC cytotoxic molecule MMAF, and exerts antitumor effects.

MMAF Hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. MMAF Hydrochloride is an effective tubulin polymerization inhibitor and is used as an antitumor compound.

MMAF sodium is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. MMAF sodium is an effective tubulin polymerization inhibitor and is used as an antitumor agent.

MMAFintermediate 1 serves as a precursor in the synthesis of MMAF (Monomethylauristatin F), an effective inhibitor of tubulin polymerization. MMAF is a cytotoxic component commonly used in antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. This compound plays a crucial role in the production of classic ADC cytotoxins.

MMAF intermediate 2 is a key synthetic intermediate used in the preparation of MMAF, a potent tubulin polymerization inhibitor that serves as the cytotoxic payload in clinically validated antibody-drug conjugates, MMAF intermediate 2 support the scalable synthesis and development of next-generation ADC cytotoxins.